



Here for you

Pharmacy and Therapeutics Committee Meeting

Agenda

Wednesday, October 16, 2024

7:30 – 9:30 am

To arrange for public building access, please contact
Luke Nelson at 415-615-4269

San Francisco Health Plan
50 Beale St.
San Francisco, CA, 94105
City Hall Conference Room

- 1) Call to order – non-voting item (est. time 5 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
 - Conflict of interest check
 - Attendance/Quorum
 - Agenda overview
- 2) Informational Updates – non-voting item (est. time 5 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
Brian Ellsworth, PharmD, Pharmacy Director, San Francisco Health Plan
- 3) Review and Approval of July 17, 2024, P&T minutes – **voting item** (est. time 3 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan

ADJOURN TO CLOSED SESSION

Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan

- 4) Consent Calendar – **voting item** (est. time 5 minutes)
Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
Katrina (Katie) Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - Drug Utilization Review (DUR) Reports and/or Educational Items
 - Prime Therapeutics Retrospective DUR Quarterly Activities 2Q2024
 - Statin letter
 - Migraine Letter
 - Asthma letter
 - Quarterly Prospective DUR Report 2Q2024
- 5) Discussion and Recommendations for Changes to SFHP Formulary and Prior Authorization Criteria and Drug Utilization Review Reports for Select Drug Classes - **voting item** (est. time 55 mins)
Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
Tammie Chau, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - Gastroenterology
 - Bile Salts Class Review
 - Hepatology
 - Rezdifra™ (resmetirom) Monograph
 - Nephrology
 - Potassium Binders Class Review
 - Neurology



Here for you

Pharmacy and Therapeutics Committee Meeting

Agenda

- Agamree® (vamorolone) Monograph
 - Zilbrysq® (zilucoplan) Monograph
 - Psychiatry
 - Antipsychotics Class Review
 - Antipsychotics DUR Analysis
 - Pulmonary
 - Asthma/COPD Class Review
 - Pulmonary Biologics Class Review
 - Rheumatology
 - Gout Class Review
- 6) DUR Program Updates, Reports, and/or Educational Items – non-voting item (est. time 15 minutes)
Jessica Shost, PharmD, Clinical Pharmacist, San Francisco Health Plan
- Fraud, Waste and Abuse (FWA) DUR Report: Multiple Providers and Multiple Pharmacies 2Q2024

RECONVENE IN OPEN SESSION

Summary of Closed Session – non-voting item (est. time 5 minutes)

Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan

- 7) Annual Pharmacy Policies and Procedures (P&Ps) Review – **voting item** (est. time 5 minutes)
Sue Chan, Pharmacy Compliance Program Manager, San Francisco Health Plan
- Pharm-02 Pharmacy Prior Authorization
 - Pharm-03 Pharmacy Network Credentialing
 - Pharm-14 Pharmacy Drug Utilization Review (DUR) Program
- 8) Review and Approval of Prior Authorization Criteria Interim Changes – **voting item** (est. time 4 minutes)
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
- 9) Review and Approval of Formulary Interim Changes – **voting item** (est. time 3 minutes)
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
- 10) Appendix: Prime Therapeutics Pipeline Report 2Q2024– non-voting item (est. time 5 minutes)
Ai Quynh Nguyen, PharmD, Pharmacist Account Manager, Prime Therapeutics
- 11) Adjournment
- Upcoming P&T Committee meeting dates
 - **Wednesday, January 15, 2025**
 - **Wednesday, April 16, 2025**
 - **Wednesday, July 16, 2025**
 - **Wednesday, October 15, 2025**